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Abstract  
BACKGROUND: Lamivudine is a nucleoside analogue antiretroviral drug, known for its low toxicity 
at clinically prescribed dose. However, the toxicity or mechanism of toxicity and target tissue effects 
during prolonged administration of higher doses were hardly given sufficient laboratory attention.  
AIM: The present work was designed to investigate the biochemical and histopathological changes 
in the liver of rat administered with prolonged doses of lamivudine. 
MATERIAL AND METHODS: Lamivudine in multiple doses of five ranging from 4 mg/kg to 2500 
mg/kg were administered, in vitro, by injection into the air-sac of 10–day old fertile embryonated 
eggs of Gallus domesticus. Also, female rats of the Wistar strain received oral doses, up to 500 
mg/kg singly or repeatedly for 15 or 45 days, respectively. Spectrophotometric techniques were 
employed to monitor activities of the aminotransferases (ALT and AST), γ–glutamyltransferase 
(GGT) and total protein concentration in serum while activities of glutathione S–transferase (GST), 
GGT and superoxide dismutase (SOD) as well as concentrations of malondialdehyde (MDA) and 
protein were determined in liver. Histopathological studies were carried out on liver. Data were 
analysed using ANOVA and were considered significant when p < 0.05. 
RESULTS: The LD50 for the drug calculated from the incubation experiment was 427 mg/kg. Total 
serum protein concentration significantly reduced while enzymes activities significantly increased at 
500 mg/kg only among the repeat-dosed rats. Hepatic GGT, GST and SOD activities as well as 
MDA concentration were significantly elevated at 20 mg/kg. Histopathological studies showed 
multifocal lymphoid cell population in the liver sinusoid of the chicken and hydropic degeneration of 
hepatocytes were recorded among rats repeatedly exposed to the drug respectively at doses ≥ 100  
mg/kg.  
CONCLUSION: Lamivudine toxicity in rat liver appeared to be mediated by oxidative stress. 
 
 
 
 
 
 
Introduction 
 
Lamivudine is a cytidine - analogue 
antiretroviral pro-drug. It is metabolically activated into 
51-triphosphorylated derivative by cytosolic kinases in 
a step-wise manner in the liver. The actively 
metabolised drug inhibits polymerase gamma, the 
enzyme that catalyses the synthesis of mitochondrial 
DNA which may lead to mitochondrial dysfunction in 
the susceptible tissue [1] with the accompanied 
clinical effects. Oxidative stress, an imbalance 
between prooxidant and antioxidant levels favouring 
the former may arise profoundly as a result of 
mitochondrial dysfunction, underlies mechanism of a 
number of drug toxicities [2, 3]. 
 Lamivudine is largely excreted in the urine 
unchanged or to a minor extent as a trans-sulphoxide 
[4]. Although the drug has been reported to have 
limited toxicity relative to its pharmacologic 
counterparts [5], pancreatitis [6], polyneuropathy [7] 
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and Parkinsonism [8] have been documented in 
patients on prolonged therapy.  
   Generally, much of the toxicologic 
information about this drug were obtained from clinical 
experience and the drug effects on liver especially 
following prolonged therapy at high doses, had not 
been precisely determined.  
Therefore, the objective of this work was to 
establish toxic effects of the drug on rat liver at supra-
therapeutic doses and specifically the mechanism of 
the toxicity. 
 
 
Materials and Methods 
 
Standard solutions of the drug (Lamivir brand 
containing 150 mg lamivudine) were prepared in 
normal saline or in distilled water. 
 
Embryonic in vitro study 
This was carried out according to the method 
of Gabliks et al., [9]. An aliquot of 0.5 ml of the drug in 
normal saline equivalent to 4, 20, 100, 500 or 2,500 
mg/kg was injected into the chorioallantoic sac of 10-
day old fertile embryonated egg (average weight 55 g) 
of Gallus domesticus, using 30 eggs per dose level. 
An aliquot of 0.5 ml normal saline only, injected into 
each embryonated egg of equal number served as the 
control. The response dose (RD50) was calculated 
from the data obtained using the normograph of Tint 
and Gillen [10]. 
 
Animal experiments 
Four dose levels, 4, 20, 100, and 500 mg/kg 
[11, 12], in maximum volume of 2ml. normal saline 
were adopted. The start dose was the recommended 
therapeutic dose for humans. The drug was 
administered orally in single doses to the adult female 
rats of Wistar strain. There were six rats per dose 
level. The control rats of equal number received 2ml. 
of normal saline only. Another group of rats on similar 
dose regimens were then placed on repeated (daily) 
oral administration. Both animal groups were 
observed for 14 and 45 days respectively in individual 
plastic animal cages. All the animals had access to 
normal chow and potable water ad libitum.  
                                                              
Sample preparations 
Serum samples were prepared from the rat 
blood and stored in vacutainers. Livers were carefully 
removed rapidly, washed off blood as well as 
connective tissues with 1.15% ice-cold KCl solution. 
Homogenization of the sample took place in ice-cold 
0.25 M sucrose solution buffered at pH 7.4 with 40 
mM Tris.HCl with a Potter Elvherjem homogenizer. 
Each sample homogenate was centrifuged at 8000g 
for 10 minutes in 20% (w/v) buffered medium. The 
pellet so obtained was taken up in 10ml. of the 
medium and re-centrifuged. The supernatants were 
centrifuged at 12000g for 10 minutes to remove light 
mitochondria [13]. The final supernatants were 
combined and used as post-mitochondrial fraction for 
the biochemical analyses. 
 
Analytical methods 
In the sera, aspartate and alanine 
aminotransferases activities were determined using 
RANDOX (UK) Laboratories analytical kits while total 
protein concentrations were determined according to 
Lowry et al., [14], and malondialdehyde (MDA) 
concentration according to Yuda et al. [15]. Activity of 
glutathione S- transferase was measured using the 
method of Habig et al. [16], that of γ- 
glutamyltransferase (GGT) was by [17] while that of 
superoxide dismutase (SOD) was by [18], respectively 
in the hepatic post-mitochondrial fractions.  
 
Histopathology 
The harvested liver tissues of both the chicks 
and rats were fixed in formol saline for 24 hours and 
dehydrated thereafter using ethanol in ascending 
concentrations starting from 70%. The tissues were 
cleared using xylene and infiltrated with melted wax 
followed by embedding, sectioning, rehydration in 
descending grades of ethanol in that order and finally 
staining with hematoxylene and eosin. 
Histopathological studies were carried out on the 
prepared slides and examined under light microscope. 
 
Statistical analyses 
One-way analysis of variance (ANOVA) with 
Dunnett multiple comparisons unpaired t-test    was 
employed. Data were considered significant when 
p<0.05. 
 
 
Results and Discussion 
 
The response dose (RD50), the drug dose that 
killed/caused unhatching of half the population of the 
chick embryos was calculated as 427 mg/kg (data not 
shown). No drug-induced mortality among the rats 
was recorded. Body-weight gain was comparatively 
reduced in rats on repeated administrations (Tables 1) 
which might be drug - related (r = - 0.822).                                                          
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Table 1: Body-weight change of rats following repeated daily 
oral doses of lamivudine for 45 days٭ 
Lamivudine 
dose (mg/Kg/day) 
Initial weight (g) Final weight (g) Weight change (%) 
0.0 158.7 ± 2.62 208.2 ± 4.74 +31.2 ± 1.14 
4.0 140.4 ± 2.45 177.7 ± 6.04† +28.0 ± 1.14 
20.0 117.0 ± 4.04 142.4 ± 7.14† +21.3 ± 2.12 
100.0 163.4 ± 3.80 197.9 ± 6.41† +21.0 ± 1.25 
500.0 150.1 ± 4.78 172.1 ± 7.31† +14.5 ± 1.47 
٭Values are means ± S.E.M.  †Means significantly different when compared with the 
control P<0.05 otherwise p>0.05 (Paired t- test). 
 
There were no statistically significant changes 
in the activities of the serum enzymes as well as 
protein concentration in rats dosed with single oral 
administrations when compared with the control or 
with 4 mg/kg (data not shown). However, the 
increased serum enzymes activities accompanied with 
reduced serum protein concentration in rats 
repeatedly exposed to the drug were statistically 
significant at 500 mg/kg only, when compared with the 
control (Table 2).  
Table 2: Sera of rats following daily oral doses of 3TC for 45 
days٭ 
Lamivudine    
dose (mg/kg/d) 
ALT (I.U/L) AST (I.U/L) GGT (I.U/L) 
Total Protein 
(mg/ml) 
0.0  23.3087 ±1.51 42.5710 ± 1.96  14.3075±0.72 6.134 ± 0.61 
4.0 25.0575  ± 1.31 43.1957 ± 1.18 13.8633 ± 0.81 6.186 ± 0.35 
20.0  27.7433 ± 1.99 43.4660 ± 1.38 15.2150 ± 1.12 5.325 ± 0.34 
100.0  28.4802 ± 2.53 44.7498 ± 2.34 15.8780 ± 2.65 4.791 ± 0.45 
500.0 33.1847 ± 3.96† 56.4205±7.17†  16.2613 ± 1.78†  3.945 ± 0.20‡ 
٭Values are means ± S.E.M. Mean significantly different from the control † p<0.05; 
‡p<0.01, otherwise p>0.05. 
 
The specific activities of hepatic GST and 
GGT in rats were found to increase with applied doses 
(Table 3). The specific activities of both enzymes were 
significantly increased by as little a dose as 20 mg/kg 
when compared with the control.  
Table 3: Specific activities of GST and GGT in rat livers 
following daily oral doses of 3TC for 45days
#
 
Lamivudine-doses 
(mg/kg/day) 
GST specific activity 
(U x 10
-2
/mg protein) 
GGT specific activity 
(U/mg protein) 
0.0 8.7833 ± 0.75 3.5487 ± 0.51 
4.0 11.4250 ± 1.43 6.1883 ± 1.16 
20.0 14.9767 ± 1.71
†
 10.2442 ± 1.97
†
 
100.0 15.8083 ± 1.71
†
 12.4675 ± 1.17
*∆
 
500.0 18.2333 ± 2.09
*∆
 15.3658 ± 2.24
*‡
 
#
Values are means ± S.E.M. Mean significantly different from the control †p<0.05, *p<0.01, 
and from 4mg/kg, ∆p<0.05, ‡p<0.01, otherwise p>0.05 when compared with the control. 
 
Also, the hepatic concentration of MDA and 
specific activity SOD increased in a similar fashion as 
GST and GGT (Table 4). In comparison with the 
control, the increased concentration of hepatic MDA 
was significant as from 100 mg/kg whereas the mean 
specific activity of SOD was significantly increased by 
the 20 mg/kg dose (Table 4). 
 
 
 
Table 4:  Malondialdehyde (MDA) concentrations and 
superoxide dismutase (SOD) specific activities in the rat livers 
following daily oral doses of 3TC for 45 days
# 
Lamivudinedose 
(mg/kg/day) 
Hepatic-MDA concentration 
(nmole/mg protein) 
Hepatic SOD specific activity-
(U/mg protein) 
0.0 0.0571 ± 0.01 9.9583 ± 0.70 
4.0 0.0730 ± 0.01 12.0100 ± 0.93 
20.0 0.1560 ± 0.03 14.7017 ± 1.49
*
 
100.0 0.1647 ± 0.03
†
 14.7383 ± 1.20
*
 
500.0 0.2228 ± 0.04* ‡ 16.5267 ± 1.32
*∆
 
#Values are means ± S.E.M. Mean significantly different from the control †p<0.05, * 
p<0.01 and different from 4mg/kg , ∆ p<0.05, ‡p<0.01 , otherwise p>0.05 when compared 
with the control. 
 
The mean ratio of the liver-weight to the total 
body-weight among the rats repeatedly exposed to 
the drug increased with the dose. The effect of 500 
mg/kg was very significant (Table 5). 
Table 5: Liver-weight/Body-weight change in the rats following 
daily oral doses of 3TC for 45 days
#
  
Lamivudine dose (mg/kg/day) Liver/Body weight ratio (x 10
-5
) 
0.0 3.4683 ± 0.051 
4.0 3.4950 ± 0.077 
20.0 3.5900 ± 0.065 
100.0 3.6200 ± 0.055 
500.0 4.0067 ± 0.102
٭‡ 
#Values are means ± S.E.M. Mean significantly different, from the control 
٭
p<0.01, from 
4mg/kg 
∆
p<0.05, p<0.01 otherwise p>0.05 (not significant) when compared with the 
control. 
 
The results of the histopathologic 
investigations of the liver tissues of both the chick 
embryos and the rats following the administration of 
lamivudine are presented in Figures 1 to 6 and 7 to 11 
respectively. It was revealed that as little a dose as 4 
mg/kg, (the human therapeutic equivalent of the drug), 
produced lymphoid aggregates in the chick embryo 
livers but 20 mg/kg dose produced similar effects in 
the rats exposed repeatedly to the drug.     
 
Figure 1:  Liver (H & E ×100) of chick embryo following injection of 
0.5 ml normal saline (the control) showing no visible lesion  
 
Figure 2:  Liver (H & E ×100) of the chick embryo following injection 
of 4 mg 3TC/kg body weight showing lymphoid aggregates, very 
sparse 
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Figure 3: Liver (H&E ×100) of the chick embryo following injection of 
20 mg 3TC/kg body weight showing lymphoid aggregates very 
sparse and very mild portal congestion 
 
Figures 4: Liver (H & E × 100) of chick embryo following injection of 
100 mg 3TC/kg body weight showing moderately dense lymphoid 
compartment 
 
Figure 5:  Liver (H & E × 100) of chick embryo following injection of 
500 mg 3TC/kg body weight showing highly dense multifocal 
lymphoid cell population in the sinusoid 
 
 
Figure 6:   Liver (H & E x 100) of chick embryo following injection of 
2500 mg 3TC/kg body weight showing highly dense multifocal 
lymphoid cell population in the sinusoid  
                                                              
 
Figure 7:  Liver (H & E ×400) of the rat administered orally 0.2 ml of 
distilled water daily for 45days (the control) showing no visible 
lesion                                            
 
Figure 8:  Liver (H & E × 400) of the rat dosed orally 4 mg 3TC/kg 
body weight daily for 45days showing no visible lesion 
 
Figure 9:  Liver (H & E ×400) of the rat dosed orally 20 mg 3TC/kg 
body weight daily for 45 days showing marked sinusoidal and portal 
congestion with diffuse hydropic degeneration of hepatocytes 
 
Figure 10: Liver (H & E ×400) of the rat following daily oral dose of 
100 mg 3TC/kg body weight for 45 days showing severe diffuse 
hydropic degeneration of hepatocytes. 
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Figure 11: Liver (H & E ×400) of the rat dosed 500 mg 3TC/kg body 
weight daily for 45days showing marked sinusoidal and portal 
congestion with severe hydropic degeneration of hepatocytes. 
There is also cellular infiltration (periportal) by macrophage 
 
The fertile avian embryo is highly sensitive 
and susceptible to the toxicity of xenobiotics. In 
addition, the presence of phases 1 and 2 drug-
metabolising enzymes in the chicken embryo [19, 20] 
informed our use of the egg titration/embryonation 
technique for our in vitro toxicity studies. The LD50 427 
mg/kg, the dose responsible for the death of half the 
population of the embryos, informed our choice of 500 
mg/kg as the terminal dose in the animal experiments, 
and the dose differential in multiples of five as applied 
is in accord with the geometric progression 
requirement of moving average method of LD50 
determination [11]. 
The observed reduction in body-weight gain 
among the rats on repeated doses relative to the 
control or to those on single doses could be 
associated with the drug [21]. Body-weight is known to 
be determined by complex mechanisms regulating 
energy balance. A number of neurotransmitter 
systems acting in several hypothalamic nuclei are 
pivotal to the regulation of body fat stores. Reduced 
adipose tissue has been foremost cause of low body-
weight [22]. Abnormal fat metabolism or lipodystrophy 
has been reported as a consequence of mitochondrial 
dysfunction associated with many of the 
nucleoside/nucleotide reverse transcriptase inhibitors 
[23]. 
The increased activities of serum enzymes 
resulted from their release into blood circulation 
following structural damage to the liver cells by the 
drug 24]. The low levels of total protein in sera of 
these animals reflected negative protein turn-over 
which occurs in pathologic livers [25]. The results of 
the serum analyses in rats on single doses seemed to 
show animal recovery from the boost of the drug 
doses [26].  
GGT and GST, both GSH-dependent 
enzymes, are found in large amounts in the liver. 
Their respective increases in mean specific activities 
sustained by GSH supply, was probably an adaptive 
response to the oxidative challenge occasioned by the 
drug.         
MDA is a product of lipid peroxidation. Lipid 
peroxidation is a widely accepted mechanism of 
cellular injury and death. The elevated MDA levels in 
the rat livers suggested onset of oxidative stress 
presumably by GSH depletion [27]. The increased 
specific activity of SOD concerned with superoxide 
dismutation, might be an adaptive response to the 
sustained oxidative challenge by the drug.   
The observed increase in liver- weight/body-
weight ratio could be connected with lipodystrophy, 
abnormal fat metabolism; a clinical presentation in 
NRTI- exposed patients, associated with 
mitochondrial dysfunction [27]. Further work is needed 
to confirm lipodystrophy in lamivudine – exposed 
subject whereas data here presented could be a 
seminal contribution towards quantitative proof of 
lamivudine-induced lipodystrophy. 
             In conclusion, the result of the investigations 
suggested hepatotoxic potentials of lamivudine at high 
doses (≥ 100 mg/kg) on prolonged administration. 
Oxidative stress appeared to be the drug mechanism 
of the toxicity in rat liver. According to the reported 
British Toxicological Society rating [28], 500 mg 
3TC/kg repeatedly taken orally for such periods of 
time, was ‛harmful’ to the female Wistar rat.    
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